| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2115168 | Cancer Letters | 2007 | 13 Pages |
Abstract
NCAM is a tumour associated antigen expressed on small cell lung cancer, neuroblastoma, rhabdomyosarkoma, brain tumours, multiple myelomas and acute myeloid leukaemia. Constant and strong expression of NCAM is a prerequisite for the development of antibody-based immunotherapies. From the spectrum of existing anti-NCAM compounds, radioimmunoconjugates and immunotoxins represent the clinically most advanced and successful strategies. Here we provide an overview of the evolving field of anti-NCAM immunotherapy for cancer and discuss its indications and limitations.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Markus Jensen, Frank Berthold,